Vivian Yan Shi

Vivian Yan Shi

Auto-generated profile, based on publicly available information

Vivian Yan Shi

Department of Dermatology University of Washington Seattle Washington USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2017 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
AVAlexandra R. Vaughn
Alexandra R. Vaughn
ACAshley K. Clark
Ashley K. Clark
Raja SivamaniRaja Sivamani
Raja Sivamani
VSVivian Y. Shi
Vivian Y. Shi

15 May 2018 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
TZT.H. Zhu
T.H. Zhu
TZT.R. Zhu
T.R. Zhu
KTK.A. Tran
K.A. Tran
RSR.K. Sivamani
R.K. Sivamani
VSV.Y. Shi
V.Y. Shi

23 October 2019 in Dermatology
Verified
Journal Article
Open access
PDF file
AHAleksi J. Hendricks
Aleksi J. Hendricks
JHJennifer L. Hsiao
Jennifer L. Hsiao
MLMichelle A. Lowes
Michelle A. Lowes
VSVivian Y. Shi
Vivian Y. Shi
Hidradenitis suppurativa (HS) is a chronic inflammatory dermatosis that imparts a significant burden on patients and presents a management challenge for healthcare providers. As attention to this debilitating condition has grown over recent years, our understanding of HS pathogenesis and optimal treatment approaches continues to evolve. Nine HS treatment guidelines developed by various expert organizations have been published, encompassing therapeutic modalities ranging from topical agents to systemic therapies to procedural interventions. These guidelines demonstrate significant overlap in treatment recommendations and have all been published within the last 5 years. Therefore, we aim to compare and synthesize the recommendations of international HS treatment guidelines and to encourage inter-organizational communication for the development of consensus or staggered publication of recommendations for HS management.

3 December 2019 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
AHA.J. Hendricks
A.J. Hendricks
LEL.F. Eichenfield
L.F. Eichenfield
VSV.Y. Shi
V.Y. Shi

7 January 2019 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MMM. Maarouf
M. Maarouf
CMC.L. Maarouf
C.L. Maarouf
Gil YosipovitchGil Yosipovitch
Gil Yosipovitch
VSV.Y. Shi
V.Y. Shi

12 November 2019 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
AHAleksi J. Hendricks
Aleksi J. Hendricks
Gil YosipovitchGil Yosipovitch
Gil Yosipovitch
VSVivian Y. Shi
Vivian Y. Shi
Importance: While dupilumab has emerged as an effective treatment for moderate-to-severe atopic dermatitis (AD) since its approval in 2017, interleukin-4 and 13 blockade has also demonstrated efficacy in off-label chronic dermatologic conditions. Objective: To identify chronic dermatologic conditions in which dupilumab has demonstrated efficacy. Findings: Thirty-three reports of dupilumab use in non-AD dermatologic conditions were identified through systematic literature review. Effective use of dupilumab has been reported in case reports and case series in the treatment of chronic pruritus, prurigo nodularis, eczematous eruption of aging, allergic contact dermatitis, chronic hand eczema, alopecia areata, urticaria, eosinophilic annular erythema, bullous pemphigoid and papuloerythroderma of Ofuji. Clinical trials are underway evaluating the efficacy of dupilumab in allergic contact dermatitis, chronic hand eczema, alopecia areata, chronic spontaneous urticaria and cholinergic urticaria. Conclusions and Relevance: Overlap in immune signaling pathways between AD and chronic pruritus, eczematous eruption of aging, allergic contact dermatitis, chronic hand eczema, alopecia areata, urticaria, eosinophilic annular erythema, bullous pemphigoid and papuloerythroderma of Ofuji make these conditions candidates for dupilumab therapy when standard treatments have failed or are contraindicated. While promising as a therapeutic option, off-label prescribing of dupilumab requires consideration of challenges in insurance authorization and out-of-pocket cost to the patient.